|
Characteristics of the study population (n = 119) |
||||||
| COPD |
||||||
| Healthy (ex)smokers |
At Risk (Stage 0) |
Mild (Stage I) |
Moderate (Stage IIA) |
Moderate (Stage IIB) |
Severe (Stage III) |
|
|
|
||||||
| N |
44 |
18 |
15 |
20 |
16 |
6 |
| Males (%) |
48 |
33 |
60 |
70 |
81 |
100 |
| Age, yr |
51 (45–71) |
53 (42–61) |
54 (48–66) |
57 (46–73) |
66 (49–74) |
59 (53–69) |
| Pack yr |
24 (4–66) |
29 (2–67) |
31 (20–77) |
35 (15–77) |
36 (10–85) |
34 (12–45) |
| Current smoking(%) |
89 |
100 |
100 |
85 |
75 |
83 |
| FEV1 (%pred) |
101 (62–128) |
105 (82–132) |
93 (81–116) |
69 (51–75) |
41 (30–49) |
24 (22–28) |
|
Healthy (ex) smokers; normal spirometry, no chronic symptoms (cough, sputum production). COPD classification of COPD by severity according to the GOLD guidelines; Stage 0: normal spirometry, chronic symptoms (cough, sputum production); Stage I: FEV1/FVC < 70%, FEV1 ≥ 80 % predicted, with or without chronic symptoms (cough, sputum production, dyspnea); Stage IIA: FEV1/FVC < 70%, 50% ≥ FEV1 < 80 % predicted; Stage IIB: FEV1/FVC < 70%, 30% ≥ FEV1 < 50 % predicted; Stage III: FEV1/FVC < 70%, FEV1 < 30 % predicted or FEV1 < 50% predicted plus respiratory failure or clinical signs of right heart failure. | ||||||
van der Molen et al. Health and Quality of Life Outcomes 2003 1:13 doi:10.1186/1477-7525-1-13 |
||||||